Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 05, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details specific changes in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the following transactions notified on March 2, 2007:
- Increases (Feb 23, 2007 at $56.92/share): Dr JP Garnier (35), Dr M M Slaoui (7), Mrs C Bruck Slaoui (3), Dr R G Greig (21), Mr W Louv (5), Dr D Pulman (6), Mr D Stout (42), Mr C Viehbacher (8).
- Decreases (Feb 9, 2007 at $56.38/share): Dr M M Slaoui (54).
- Decreases (Feb 15, 2007 at $57.65/share): Dr M M Slaoui (1).
Investor Verification Points
- Verify the impact of these notional ADR allocations on the total equity holdings of the named directors.
- Confirm the current market price of GSK Ordinary Share ADRs relative to the transaction prices cited ($56.38 - $57.65).
- Review the full US Retirement Savings Plan rules to understand the mechanics of the "notional investment" mentioned.